Live search
TopFind is fetching the latest matches for your search.
We reviewed 92 live results for trastuzumab biosimilar and narrowed them down to the 3 options that look most worth comparing first.
The strongest themes across this short list are Oncology and Monoclonal Antibodies.
Sumber: Biocon Biologics Philippines Inc.
Deskripsi
A biosimilar monoclonal antibody for the treatment of HER2-positive breast and gastric cancers, available in the Philippines since 2018.
Paling cocok untuk
HER2-positive breast cancer, gastric cancer treatment and oncology therapy
Penilaian
Sumber: Celltrion Healthcare
Deskripsi
Herzuma is a biosimilar trastuzumab, a monoclonal antibody designed as a targeted oncology therapy for HER2-positive early breast cancer, metastatic breast cancer, and advanced gastric cancer. It is supplied as a powder for concentrate for solution for infusion in 150mg and 440mg vials.
Paling cocok untuk
HER2-positive breast cancer, metastatic gastric cancer patients, cost-effective targeted therapy and oncology infusion treatment
Penilaian
Sumber: Pfizer Philippines Inc.
Deskripsi
Trazimera is a monoclonal antibody biosimilar for the treatment of HER2-positive breast and stomach cancers, receiving PH FDA approval in 2022.
Paling cocok untuk
HER2-positive breast cancer, stomach cancer and targeted oncology therapy
Penilaian
| Bandingkan | Trastuzumab Biosimilar | Herzuma (Trastuzumab) | Trazimera (Trastuzumab) |
|---|---|---|---|
| Sumber | Biocon Biologics Philippines Inc. | Celltrion Healthcare | Pfizer Philippines Inc. |
| Deskripsi | A biosimilar monoclonal antibody for the treatment of HER2-positive breast and gastric cancers, available in the Philippines since 2018. | Herzuma is a biosimilar trastuzumab, a monoclonal antibody designed as a targeted oncology therapy for HER2-positive early breast cancer, metastatic breast cancer, and advanced gastric cancer. It is supplied as a powder for concentrate for solution for infusion in 150mg and 440mg vials. | Trazimera is a monoclonal antibody biosimilar for the treatment of HER2-positive breast and stomach cancers, receiving PH FDA approval in 2022. |
| Paling cocok untuk | HER2-positive breast cancer, gastric cancer treatment and oncology therapy | HER2-positive breast cancer, metastatic gastric cancer patients, cost-effective targeted therapy and oncology infusion treatment | HER2-positive breast cancer, stomach cancer and targeted oncology therapy |
| Tag | |||
| Aksi | Lihat detail | Lihat detail | Lihat detail |
| Penilaian |
Jika Anda ingin memulai dari opsi yang paling seimbang, saya merekomendasikan:
"Trastuzumab Biosimilar from Biocon Biologics Philippines Inc.."
Saya memilih ini karena This biosimilar provides a targeted oncology treatment for HER2-positive cancers with a proven local track record.